Manufacturer
JOHNSON & JOHNSON SDN BHD
Content
Golimumab
Indication
In combination w/ methotrexate (MTX) for moderate to severe active RA in adults when response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate; active, severe & progressive RA in adults not previously treated w/ MTX. Alone or in combination w/ MTX for active psoriatic arthritis (PsA) in adults when response to previous DMARD therapy has been inadequate. Active ankylosing spondylitis (AS) in adults when response to conventional therapy has been inadequate. Adult w/ severe, active non-radiographic axial spondyloarthritis (nr-Axial SpA) w/ objective signs of inflammation as indicated by elevated C-reactive protein &/or MRI evidence, who have inadequate response to, or are intolerant to NSAIDs. Moderate to severe active ulcerative colitis in adults who had an inadequate response to conventional therapy eg, corticosteroids & 6-mercaptopurine or azathioprine, or who are intolerant to or have medical CI for such therapies.
Instruction
SIMPONI is administered by subcutaneous injection or intravenous infusion.
Drug interaction
Not recommended w/ concurrent use of anakinra, etanercept, abatacept & other biological therapeutics. Not to be given concurrently w/ live vaccines. Higher steady-state trough conc w/ SC MTX.
Malaysia
